Editor´s Pick

      New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

      INGELHEIM, Germany & RIDGEFIELD, Conn.--(BUSINESS WIRE)--Today, Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile...

      Parsemus Foundation: Metformin Drastically Reduces COVID Hospitalization, Study Shows

      SAN FRANCISCO--(BUSINESS WIRE)--The widely available diabetes drug metformin reduced serious outcomes by more than half if started within 4 days of COVID symptoms in...

      Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology

      PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement...

      Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

      NEW YORK & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have...

      PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan

      BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs,...

      Recent Articles

      Get a free copy of "Cracking the Generics Code"

      Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.